HK Stock Market Move | CLOVER BIO-B(02197) rose by over 5%, expected to turn losses into profits in the first half of the year, earning up to 12.04 billion yuan.

CLOVER BIO-B (02197) surged more than 5%, reaching a 5.41% increase at the time of writing, at 1.56 Hong Kong dollars, with a trading volume of 2.9144 million Hong Kong dollars. On the news front, Clover Biopharmaceuticals announced a profit alert this morning, expecting to record a net profit of approximately 957 million to 1.204 billion yuan for the six months ending on June 30, 2026, compared to a net loss of approximately 1.013 billion yuan in the same period last year. The turnaround from loss to profit is mainly due to the settlement agreement signed by its wholly-owned subsidiary, Clover Biopharmaceuticals (Hong Kong), with the Global Alliance for Vaccines and Immunization (Gavi) on March 22 this year, resulting in non-recurring accounting gains of approximately 1.089 to 1.336 billion yuan. The company's board emphasized that this accounting gain is of a non-recurring nature. Excluding the impact of this gain, the group is expected to continue to record a net loss for the six months ending on June 30, 2026, mainly due to ongoing investment in research and development activities and a lack of significant operating income.